Compare CL & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CL | EW |
|---|---|---|
| Founded | 1806 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.0B | 49.5B |
| IPO Year | N/A | 2000 |
| Metric | CL | EW |
|---|---|---|
| Price | $84.67 | $84.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 21 |
| Target Price | $90.60 | ★ $96.37 |
| AVG Volume (30 Days) | ★ 6.2M | 3.2M |
| Earning Date | 01-30-2026 | 02-10-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ 2.56 | N/A |
| EPS | ★ 3.57 | 2.33 |
| Revenue | ★ $20,097,000,000.00 | $5,883,800,000.00 |
| Revenue This Year | $3.86 | $14.29 |
| Revenue Next Year | $3.36 | $9.68 |
| P/E Ratio | ★ $23.62 | $36.26 |
| Revenue Growth | N/A | ★ 10.60 |
| 52 Week Low | $74.55 | $65.94 |
| 52 Week High | $100.18 | $87.89 |
| Indicator | CL | EW |
|---|---|---|
| Relative Strength Index (RSI) | 69.41 | 48.32 |
| Support Level | $75.96 | $81.26 |
| Resistance Level | $85.09 | $86.10 |
| Average True Range (ATR) | 1.42 | 1.74 |
| MACD | 0.65 | -0.22 |
| Stochastic Oscillator | 93.00 | 48.87 |
Since its founding in 1806, Colgate-Palmolive has grown into a leading player in the household and personal care industry. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and home care products sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one-fifth of sales), which sells a majority of its products through veterinarians and specialty pet retailers.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.